AU2019293163B2 - Natural killer cells - Google Patents

Natural killer cells

Info

Publication number
AU2019293163B2
AU2019293163B2 AU2019293163A AU2019293163A AU2019293163B2 AU 2019293163 B2 AU2019293163 B2 AU 2019293163B2 AU 2019293163 A AU2019293163 A AU 2019293163A AU 2019293163 A AU2019293163 A AU 2019293163A AU 2019293163 B2 AU2019293163 B2 AU 2019293163B2
Authority
AU
Australia
Prior art keywords
compound
rev
erb
cells
e4bp4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019293163A
Other languages
English (en)
Other versions
AU2019293163A1 (en
Inventor
Hugh J. M. BRADY
Matthew J. Fuchter
Amaia Uriz HUARTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU2019293163A1 publication Critical patent/AU2019293163A1/en
Application granted granted Critical
Publication of AU2019293163B2 publication Critical patent/AU2019293163B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019293163A 2018-06-26 2019-06-26 Natural killer cells Active AU2019293163B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1810486.9 2018-06-26
GBGB1810486.9A GB201810486D0 (en) 2018-06-26 2018-06-26 Natural killer cells
PCT/GB2019/051803 WO2020002911A1 (en) 2018-06-26 2019-06-26 Natural killer cells

Publications (2)

Publication Number Publication Date
AU2019293163A1 AU2019293163A1 (en) 2021-01-21
AU2019293163B2 true AU2019293163B2 (en) 2025-10-23

Family

ID=63042803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019293163A Active AU2019293163B2 (en) 2018-06-26 2019-06-26 Natural killer cells

Country Status (8)

Country Link
US (1) US12377119B2 (https=)
EP (1) EP3814485A1 (https=)
JP (2) JP7527207B2 (https=)
CN (1) CN112752837A (https=)
AU (1) AU2019293163B2 (https=)
CA (1) CA3104674A1 (https=)
GB (1) GB201810486D0 (https=)
WO (1) WO2020002911A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201703476D0 (en) 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
AU2021372389A1 (en) * 2020-10-16 2023-05-11 Pelagos Pharmaceuticals, Inc. Rev-erb agonists
WO2024047368A1 (en) 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
GB202217507D0 (en) 2022-11-23 2023-01-04 Imperial College Innovations Ltd Natural killer cells
AU2024212529A1 (en) * 2023-01-27 2025-06-19 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59141562A (ja) * 1983-02-01 1984-08-14 Nippon Kayaku Co Ltd Ｎ，ｎ′−置換イミダゾ−ルカルボキサミド誘導体および農園芸用殺菌殺線虫剤
JPS60109568A (ja) * 1983-11-17 1985-06-15 Ube Ind Ltd イミダゾ−ル誘導体および農園芸用殺菌剤
WO1996038419A1 (en) * 1995-05-31 1996-12-05 Nissan Chemical Industries, Ltd. 5-pyrazolecarboxamide derivatives and plant disease control agent
WO2003040114A1 (en) * 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2004004655A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2018158587A1 (en) * 2017-03-03 2018-09-07 Imperial Innovations Limited Natural killer cells
WO2018178666A1 (en) * 2017-03-28 2018-10-04 Imperial Innovations Limited Natural killer cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
WO2000046204A1 (en) 1999-02-04 2000-08-10 Sk Corporation Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US20090062212A1 (en) 2007-05-07 2009-03-05 Elliott Richelson Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2
CA3080368A1 (en) * 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
EP3184109B1 (en) * 2009-12-29 2020-11-18 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
WO2012075412A1 (en) * 2010-12-03 2012-06-07 Michael Verneris Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
WO2012128622A1 (en) 2011-03-18 2012-09-27 Ipd-Therapeutics B.V. Generation of nk cells and nk-cell progenitors
WO2013033310A1 (en) 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
CN103710304B (zh) * 2012-09-29 2018-11-02 北京东方百奥医药开发有限公司 脂肪干细胞诱导分化为自然杀伤细胞的方法及用途
ITTO20130816A1 (it) * 2013-10-09 2015-04-10 Fond Istituto Italiano Di Tecnologia Antagonisti di rev-erb diarilalchilaminici e loro uso come farmaci
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
WO2018178663A1 (en) * 2017-03-30 2018-10-04 Parker Hannifin Manufacturing Limited A pressure swing adsorption system with a variable flow restrictor
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59141562A (ja) * 1983-02-01 1984-08-14 Nippon Kayaku Co Ltd Ｎ，ｎ′−置換イミダゾ−ルカルボキサミド誘導体および農園芸用殺菌殺線虫剤
JPS60109568A (ja) * 1983-11-17 1985-06-15 Ube Ind Ltd イミダゾ−ル誘導体および農園芸用殺菌剤
WO1996038419A1 (en) * 1995-05-31 1996-12-05 Nissan Chemical Industries, Ltd. 5-pyrazolecarboxamide derivatives and plant disease control agent
WO2003040114A1 (en) * 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2004004655A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2018158587A1 (en) * 2017-03-03 2018-09-07 Imperial Innovations Limited Natural killer cells
WO2018178666A1 (en) * 2017-03-28 2018-10-04 Imperial Innovations Limited Natural killer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAKUGAKU ZASSHI, 94(8), 934-44 CODEN: YKKZAJ; ISSN:0031-6903, 1974 *

Also Published As

Publication number Publication date
JP2021528969A (ja) 2021-10-28
US20220073880A1 (en) 2022-03-10
CA3104674A1 (en) 2020-01-02
WO2020002911A1 (en) 2020-01-02
AU2019293163A1 (en) 2021-01-21
JP2024095819A (ja) 2024-07-10
JP7527207B2 (ja) 2024-08-02
CN112752837A (zh) 2021-05-04
EP3814485A1 (en) 2021-05-05
GB201810486D0 (en) 2018-08-08
US12377119B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
AU2019293163B2 (en) Natural killer cells
JP7054529B2 (ja) Ｃｘｃｒ４阻害剤およびその使用
JP5658664B2 (ja) １，２−二置換複素環式化合物
JP2022532247A (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
CA3162687A1 (en) Asgpr-binding compounds for the degradation of extracellular proteins
CN109348714A (zh) 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
US20150087598A1 (en) Treating muc1-expressing cancers with helicase inhibitors
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP2024156758A (ja) 癌及び自己免疫疾患を治療するための組成物及び方法
JP6845531B2 (ja) 免疫チェックポイント阻害作用を有するインドールアルカロイド型化合物
ES2336047T3 (es) Derivados de 3-azabiciclo-(4,1,0)heptano para el tratamiento de la depresion.
JP7397808B2 (ja) 骨髄系新生物および固形腫瘍の処置のためのｓｅｔｂｐ１インヒビター
US20160031937A1 (en) Neural regeneration peptides and uses therefor
CN113613650B (zh) 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂
KR20240145992A (ko) 비사이클릭 프탈라진-1(2h)-온 유도체 및 관련 용도
WO2024110758A2 (en) Natural killer cells
KR20170109541A (ko) 알파9 인테그린 길항제를 사용한 골수 줄기 세포 니치로부터의 hsc의 이탈 및 방출
KR101213445B1 (ko) 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
CN110494136A (zh) 细胞保护性化合物及其用途
US20220370586A1 (en) Method of generating activated t cells for cancer therapy
WO2023077188A1 (en) Proteinaceous molecules and uses therefor
HK40010265A (en) Cancer treatment combinations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)